| Read Time: < 1 minute | Dangerous Drugs

Appellate Court Reinstates Hundreds of Incretin Mimetics Cases

November 2017 — The 9th Circuit of U.S. Court of Appeals returned the decision that the district court had misapplied the Supreme Court case Buckman Co. v Plaintiffsโ€™ Legal Committee.  They ruled that the case had been misapplied in two ways.  The first was the district court relying on Buckman to impermissibly circumscribe discovery.  The second was the court...

Continue Reading

| Read Time: 2 minutes | Car Accident

Go With Experience

If you are searching for legal counsel in Evansville, Indianapolis, Louisville, Owensboro, or surrounding communities, contact Gerling Law. Our lawyers have one purpose: to make your life better through assertive advocacy, legal experience, and a commitment to results. For over five decades, our firm has helped individuals get their lives back after an accident or when they can no...

Continue Reading

| Read Time: < 1 minute | Dangerous Drugs

Sanofiโ€™s Motion to Dismiss Denied

September 2017 — The Court denied Sanofiโ€™s motion to dismiss all counts. Reference: โ€œTaxotere Lawsuit – Permanent Hair Loss and Illegal Marketing.โ€ Drugwatch.com, 20 Apr. 2020, www.drugwatch.com/taxotere/lawsuits/

Continue Reading

| Read Time: < 1 minute | Dangerous Drugs

Study Shows Ranitidine Leads To High NDMA Levels

2016 — A Mitch study in 2016 tested urine samples of 10 people, 5 males and 5 females, who took a single 150 mg ranitidine tablet.  They found NDMA levels higher than the FDA limits.  Their urine was tested 24 hours before taking ranitidine and then 24 hours after.  The study found that the levels of NDMA in the...

Continue Reading

| Read Time: < 1 minute | Dangerous Drugs

Doctorโ€™s Research Aiding Investigation Of Link Between Incretin Mimetics and Cancer

A previous Merck researcher is now assisting litigation against such drug manufacturers over diabetes treatments that he found were linked to pancreatic cancer. Dr. Peter Butler tested Merckโ€™s drug Januvia on rats in 2008 and discovered changes in the ratsโ€™ pancreases that he worried could lead to cancer. Butlerโ€™s follow-up research to confirm the linkage is now fueling investigations...

Continue Reading

| Read Time: < 1 minute | Dangerous Drugs

GlaxoKlineSmith Ranitidine Patent Expires

1997 — In 1997, GlaxoKlineSmithโ€™s U.S. patent for ranitidine expired.ย  Competitors were now able to create generic alternatives. Reference:ย  โ€œTimeline: Popular Heartburn Medicine Zantac Pulled off Store Shelves.โ€ Reuters, Thomson Reuters, 21 Oct. 2019, www.reuters.com/article/us-health-fda-heartburn-timeline/timeline-popular-heartburn-medicine-zantac-pulled-off-store-shelves-idUSKBN1X014E.

Continue Reading

| Read Time: < 1 minute | Dangerous Drugs

Zantac Experiences Exponential Growth

1988 — In 1988, Zantac became the worldโ€™s best selling drug and one of the first drugs to ever top $1 billion in annual sales. Reference:ย  โ€œTimeline: Popular Heartburn Medicine Zantac Pulled off Store Shelves.โ€ Reuters, Thomson Reuters, 21 Oct. 2019, www.reuters.com/article/us-health-fda-heartburn-timeline/timeline-popular-heartburn-medicine-zantac-pulled-off-store-shelves-idUSKBN1X014E.

Continue Reading

| Read Time: < 1 minute | Dangerous Drugs

Zantac Approved by FDA

1983 — Zantac was first approved by the FDA and sold in the U.S. in 1983. Reference:ย  โ€œTimeline: Popular Heartburn Medicine Zantac Pulled off Store Shelves.โ€ Reuters, Thomson Reuters, 21 Oct. 2019, www.reuters.com/article/us-health-fda-heartburn-timeline/timeline-popular-heartburn-medicine-zantac-pulled-off-store-shelves-idUSKBN1X014E.

Continue Reading